NIH Accused of Interfering with Ethics Probe

A watchdog group claims that the federal agency improperly influenced the investigation of a study involving the treatment of preterm infants.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, USAIDLast year, the US government’s Office of Human Research Protections (OHRP) conducted an independent investigation of alleged ethical lapses in a clinical trial that tested the effects of administering either high or low levels of oxygen to preterm infants. But it turns out that investigation wasn’t so independent after all, according to federal watchdog group Public Citizen. On Tuesday (May 20) the group released e-mails between officials at the National Institutes of Health (NIH) and those at OHRP conducting the ethical investigation of the $20 million, 23-hospital SUPPORT study.

Public Citizen, along with members of Congress, is calling for an investigation of top brass at the Department of Health and Human Services (HHS), which administers the NIH, over the alleged interference. “This interference involved NIH officials reviewing and editing a series of drafts of a pending OHRP compliance oversight determination letter regarding the SUPPORT study, as well as apparently allowing NIH to influence the timing of the release of that letter,” wrote Public Citizen to the HHS Inspector General in a letter that was cosigned by a number of academic researchers.

The SUPPORT trial ran from 2005 to 2009 and recruited more than 1,300 extremely premature babies, treating them with either low or high concentrations of oxygen (O2)—levels that were all within then-accepted standards ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies